Clinical Trial Update: Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis [EARLY_Phase 1]

View source ↗

Summary

Northwestern University’s early-phase trial of siltuximab for myelofibrosis, including primary, post-polycythemia vera, and post-essential thrombocythemia cases…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Polycythemia Vera
• Thrombocytopenia

Drugs mentioned

• Sylvant (siltuximab)

Snippet

Sponsor: Northwestern University | Conditions: Myelofibrosis, Polycythemia Vera | EARLY_Phase 1 | Status: WITHDRAWN